Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial
Sarah Baker, Will Jiang, Benjamin Mou, C. Lund, Mitchell Liu, Alanah Bergman, Devin Schellenberg, Abraham Alexander, Hannah Carolan, Siavash Atrchian, Nick Chng, Quinn Matthews, Gregory Arbour, Alexander Benny, Scott Tyldesley, Robert Olson
Topics & Concepts
SABR volatility modelMedicineHazard ratioInternal medicinePopulationConfidence intervalProgression-free survivalClinical endpointInterquartile rangeOncologyRandomized controlled trialSurgeryChemotherapyEnvironmental healthVolatility (finance)Financial economicsEconomicsStochastic volatilityHepatocellular Carcinoma Treatment and PrognosisManagement of metastatic bone diseaseCancer Research and Treatments